Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

Table 3

Disease status of ROP patients, by ranibizumab or bevacizumab treatment.

	Ranibizumab ()	Bevacizumab ()
Zone, N (%)			0.02
I	7 (27%)	2 (6%)
II	19 (73%)	34 (94%)
Stage, N (%)
2	0 (0%)	3 (8%)	0.25
3	26 (100%)	33 (92%)

Fisher’s exact test.